These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12623001)

  • 41. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
    Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
    Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives.
    Press RR; de Fijter JW; Guchelaar HJ
    Curr Pharm Des; 2010; 16(2):176-86. PubMed ID: 20205663
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative study of the cellular pharmacodynamics of calcineurin inhibitors between patients with chronic renal failure awaiting renal transplantation and cirrhosis patients awaiting liver transplantation.
    Kihara Y; Matsuno N; Mijiti A; Nagao T; Takeuchi H; Unezaki S; Hirano T
    Cell Transplant; 2009; 18(5):639-46. PubMed ID: 19775526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The choice of calcineurin inhibitor does not influence centrilobular necrosis after orthotopic liver transplantation.
    Hassoun Z; Shah V; Petrovic LM
    Transplant Proc; 2002 Aug; 34(5):1519-20. PubMed ID: 12176464
    [No Abstract]   [Full Text] [Related]  

  • 45. Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence.
    Iskedjian M; Piwko C; Shear NH; Langley RG; Einarson TR
    Am J Clin Dermatol; 2004; 5(4):267-79. PubMed ID: 15301573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The CARI guidelines. Choice of calcineurin inhibitors in adult renal transplantation: effects on transplant outcomes.
    Pilmore H;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S88-97. PubMed ID: 17316287
    [No Abstract]   [Full Text] [Related]  

  • 47. Systemic ciclosporin and tacrolimus in dermatology.
    Madan V; Griffiths CE
    Dermatol Ther; 2007; 20(4):239-50. PubMed ID: 17970889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors.
    Gordon MK; Kraus M; van Besien K
    Leuk Lymphoma; 2007 Apr; 48(4):816-8. PubMed ID: 17454644
    [No Abstract]   [Full Text] [Related]  

  • 49. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
    Schiff J; Cole E; Cantarovich M
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):374-84. PubMed ID: 17699437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Long term management of childhood atopic dermatitis with calcineurin inhibitors].
    Thaçi D
    Hautarzt; 2003 May; 54(5):418-23. PubMed ID: 12719861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of tacrolimus and clobetasol in the treatment of oral lichen planus: a systematic review and meta-analysis.
    Chamani G; Rad M; Zarei MR; Lotfi S; Sadeghi M; Ahmadi Z
    Int J Dermatol; 2015 Sep; 54(9):996-1004. PubMed ID: 26204904
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Calcineurin inhibitors and calcineurin-NFAT system].
    Amasaki Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2010; 33(5):249-61. PubMed ID: 21048386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes.
    Fiorentino DF; Chen RO; Stewart DB; Brown KK; Sundram UN
    Br J Dermatol; 2011 May; 164(5):996-1003. PubMed ID: 21166661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications.
    van Gelder T; Klupp J; Sawamoto T; Christians U; Morris RE
    Transplant Proc; 2001 May; 33(3):2420-1. PubMed ID: 11377580
    [No Abstract]   [Full Text] [Related]  

  • 55. Insulin requirement after a renal transplant in patients with type 2 diabetes: the choice of calcineurin inhibitors.
    van den Hoogen MW; van der Hoeven AM; Hilbrands LB
    Exp Clin Transplant; 2013 Jun; 11(3):234-8. PubMed ID: 23432070
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.
    Fonacier L; Spergel J; Charlesworth EN; Weldon D; Beltrani V; Bernhisel-Broadbent J; Boguniewicz M; Leung DY; ;
    J Allergy Clin Immunol; 2005 Jun; 115(6):1249-53. PubMed ID: 15940142
    [No Abstract]   [Full Text] [Related]  

  • 57. Topical pimecrolimus in the treatment of seborrheic dermatitis.
    Brownell I; Quan LT; Hsu S
    Dermatol Online J; 2003 Aug; 9(3):13. PubMed ID: 12952760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.
    Thaçi D; Salgo R
    Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun; 16(2):58, 60-62. PubMed ID: 17992459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Practice experience with topical calcineurin inhibitors].
    Lübbe J
    Hautarzt; 2003 May; 54(5):432-9. PubMed ID: 12719863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interaction of cyclosporine and FK506 with diuretics in transplant patients.
    Arthur JM; Shamim S
    Kidney Int; 2000 Jul; 58(1):325-30. PubMed ID: 10886578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.